As the most natural way to preserve public wellbeing, preventive and therapeutic vaccinations must have essential roles. Large organizations and companies have started implementing SARS-CoV-2 preventive vaccinations. Hence, in this study, we aimed to update the vaccine evolution for SARS-CoV-2....
BNT162b2 mRNA-based vaccine was developed by the Pfizer BioNtech, Fousun pharma. BioNtech is the first company to register for the FDA approval of their candidate COVID-19 vaccine. BNT162b2 is a lipid nanoparticle-based RNA vaccine (with nucleoside-modifications), encoding the SARS-CoV-2 full...
The recent emergence of different variants of SARS-CoV-2 is becoming a new threat for the world and a challenge for scientists to introduce the most influential vaccine against COVID-19. The possibility of natural and vaccine-induced immunity in variants finds it necessary to establish next-...
GENEVA, Jan. 11 (Xinhua) -- The World Health Organization (WHO) said Tuesday that current COVID-19 vaccines may need to be updated if they are to provide continued protection against emerging variants, including Omicron. WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-...
covid-19-vaccine-candidate-cvncov/), well below the efficacies reported for the BionTech-Pfizer and Moderna vaccines46,47and below the requirement of at least 50% efficacy proposed by WHO (https://www.who.int/publications/m/item/considerations-for-the-assessment-of-covid-19-vaccines-for-...
In October 2017, the US Food and Drug Administration approved the recombinant shingles vaccine (marketed as Shingrix) as a replacement for the live-virus vaccine because it was more effective at protecting people aged 50 years or older against herpes zoster, or shingles. Now an observational ...
Therapy of COVID-19 with modern medicine and vaccine The present clinical methods for COVID-19 treatment mainly include antiviral and antibacterial drugs, anti-inflammatory drugs, anti-SARS-CoV-2 antibody, oxygen therapy, and intestinal microecological agents and plasma from patients in rehabilitation...
How many people plan to take a COVID-19 vaccine? Our understanding is that the number of Americans who plan to refuse avaccinefor COVID-19, when it becomes available, is quite pervasive. Somewhere between 1 in 5 to1 in 3 Americansplan to refuse a vaccine depending on the survey and ho...
Their labs and facilities helped develop novel tests, aided in drug screens, conducted vaccine research, and analyzed population cohort data. This shift in research focus has been made possible by increased flexibility in federal grant mechanisms. Specifically, the National Institutes of Health offered...
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently was declared a pandemic by world health organization (WHO) Due to sudden outbreaks, currently, no completely effective vaccine or drug is clinically approved. Several therapeutic strategies ...